Can Trintellix (vortioxetine) cause itching (pruritus)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 19, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Can Trintellix Cause Itching?

Yes, Trintellix (vortioxetine) can cause itching (pruritus), and this is a recognized adverse effect listed in the FDA drug label. Pruritus occurs in approximately 1-3% of patients taking Trintellix at therapeutic doses, with higher rates observed at higher doses 1.

Evidence from FDA Drug Label

The FDA label for Trintellix explicitly lists pruritus (including pruritus generalized) as a common adverse reaction occurring in ≥2% of patients 1. In controlled clinical trials:

  • Pruritus occurred in 1-3% of patients across different doses (5-20 mg/day)
  • The incidence was dose-related, with higher rates at 15-20 mg/day (3%) compared to 5 mg/day (1%)
  • Placebo rate was only 1%, confirming this is a drug-related effect 1

Overdose Context

Importantly, generalized pruritus is specifically mentioned as a symptom of Trintellix overdose (40-75 mg range), appearing alongside nausea, dizziness, diarrhea, and flushing 1. This further confirms pruritus as a direct pharmacological effect of vortioxetine.

Supporting Research Evidence

Recent pharmacovigilance studies corroborate these findings:

  • A 2025 FAERS database analysis identified pruritus as a significant adverse event signal for vortioxetine, with higher reporting in females 2
  • A 2022 post-marketing analysis found pruritus among the distinct adverse event patterns reported with vortioxetine 3
  • A 2021 safety review documented excessive itching and pruritus generalized as unlisted adverse reactions with probable causality 4

Clinical Management Approach

If a patient develops itching on Trintellix:

  1. Confirm the temporal relationship - Did itching start after initiating Trintellix or increasing the dose?

  2. Assess severity:

    • Mild/localized: Continue current dose, apply topical moderate-to-high potency corticosteroids (e.g., mometasone 0.1% or betamethasone 0.1% ointment) 5
    • Moderate (widespread/intermittent): Add oral antihistamines (loratadine 10 mg daily for daytime; diphenhydramine 25-50 mg for nighttime) 5
    • Severe (constant, disrupting sleep/daily activities): Consider dose reduction or switching antidepressants
  3. Rule out other causes - The British Association of Dermatologists guidelines emphasize obtaining a complete medication history, as drug-induced pruritus requires consideration of all medications 6

  4. If antihistamines fail: GABA agonists (gabapentin 900-3600 mg/day or pregabalin 25-150 mg/day) can be effective for refractory pruritus 5

  5. Supportive measures:

    • Aggressive moisturization with urea-based creams
    • Avoid hot showers and irritating soaps
    • Consider menthol 0.5% topical preparations 5

Important Caveats

  • Nearly half of vortioxetine adverse event reports come from consumers rather than healthcare professionals, which may introduce reporting bias but also highlights the real-world impact of these symptoms 2

  • Pruritus typically occurs early in treatment (median onset 7 days), with 75% of cases occurring within the first month 2

  • The mechanism is unclear but may relate to vortioxetine's multimodal serotonergic activity, particularly its 5-HT3 receptor antagonism and effects on histamine pathways 4

  • Gender differences exist: Females report pruritus more frequently than males with vortioxetine 2

Bottom line: If itching is mild and tolerable, symptomatic treatment with topical steroids and antihistamines is reasonable. If moderate to severe or significantly impacting quality of life, dose reduction or switching to an alternative antidepressant should be strongly considered. The risk-benefit analysis must prioritize the patient's overall quality of life, not just depression control.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.